Publications by authors named "Mahesh Radhakrishnan"

Claim this Profile
G
Galantamine as add-on therapy to escitalopram: enhancing antidepressant therapeutic potential via. Targeting α7nAChR/BDNF/KYN signalling.
Shivanshu Bajaj, Radhakrishnan Mahesh

Psychopharmacology (Berl)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Converged avenues: depression and Alzheimer's disease- shared pathophysiology and novel therapeutics.
Shivanshu Bajaj, Radhakrishnan Mahesh

Mol Biol Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach.
Yeshwant Kurhe, Radhakrishnan Mahesh

Indian J Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular modifications by regulating cAMP signaling and oxidant-antioxidant defence mechanisms, produce antidepressant-like effect: A possible mechanism of etazolate aftermaths of impact accelerated traumatic brain injury in rat model.
Ankur Jindal, Radhakrishnan Mahesh, Shvetank Bhatt, Dilip Pandey

Neurochem Int· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel class of Plasmodial ClpP protease inhibitors as potential antimalarial agents.
Sourabh Mundra, Vandana Thakur, Angelica M Bello, Sumit Rathore, Mohd Asad, Radhakrishnan Mahesh

Bioorg Med Chem· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats.
Shvetank Bhatt, Radhakrishnan Mahesh, Ankur Jindal, Thangaraj Devadoss

J Basic Clin Physiol Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice.
Shvetank Bhatt, Radhakrishnan Mahesh, Thangaraj Devadoss, Ankur Jindal

J Basic Clin Physiol Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
Dilip Kumar Pandey, Thangraj Devadoss, Neha Modak, Radhakrishnan Mahesh

Indian J Med Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice.
Yeshwant Kurhe, Radhakrishnan Mahesh

Neurobiol Stress· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5HT3 receptors: Target for new antidepressant drugs.
Deepali Gupta, Visakh Prabhakar, Mahesh Radhakrishnan

Neurosci Biobehav Rev· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.
Deepali Gupta, Devadoss Thangaraj, Mahesh Radhakrishnan

Behav Brain Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes-associated depression: the serotonergic system as a novel multifunctional target.
Visakh Prabhakar, Deepali Gupta, Prateek Kanade, Mahesh Radhakrishnan

Indian J Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention.
Yeshwant Kurhe, Radhakrishnan Mahesh

Asian J Psychiatr· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Yeshwant Kurhe, Radhakrishnan Mahesh

Pharmacol Biochem Behav· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system.
Ankur Jindal, Radhakrishnan Mahesh, Shvetank Bhatt

Pharmacol Biochem Behav· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents.
Sai Kumar Chakka, Mohammad Kalamuddin, Srividhya Sundararaman, Lianhu Wei, Sourabh Mundra, Radhakrishnan Mahesh

Bioorg Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice.
Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurhe

Steroids· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery.
Deepali Gupta, Mahesh Radhakrishnan, Devadoss Thangaraj, Yeshwant Kurhe

J Pharm Bioallied Sci· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Yeshwant Kurhe, Radhakrishnan Mahesh, Thangaraj Devadoss

Biochem Biophys Res Commun· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: novel 5-HT3 receptor antagonists with antidepressant-like activity.
Arghya K Dhar, Radhakrishnan Mahesh, Ankur Jindal, Shvetank Bhatt

Arch Pharm (Weinheim)· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurhe

Eur J Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurhe, Devadoss Thangaraj, Visakh Prabhakar

Acta Pharmacol Sin· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety.
Deepali Gupta, Mahesh Radhakrishnan, Yeshwant Kurhe

Eur J Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences.
Shvetank Bhatt, Radhakrishnan Mahesh, Ankur Jindal, Thangaraj Devadoss

Pharmacol Rep· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant-like effect of a novel 5-HT3 receptor antagonist N-(benzo[d] thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide 6k using rodents behavioral battery tests.
Yeshwant Kurhe, Radhakrishnan Mahesh, Thangaraj Devadoss, Deepali Gupta

J Pharmacol Pharmacother· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis